{"id":803223,"date":"2025-01-22T08:08:55","date_gmt":"2025-01-22T13:08:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/"},"modified":"2025-01-22T08:08:55","modified_gmt":"2025-01-22T13:08:55","slug":"absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/","title":{"rendered":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">VANCOUVER, Wash. and NEW YORK, Jan.  22, 2025  (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.<\/p>\n<p align=\"left\">Absci management is scheduled to participate in a fireside chat on Wednesday, February 5<sup>th<\/sup> at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company\u2019s investor relations website at: investors.absci.com.<\/p>\n<p align=\"justify\">\n        <strong>About Absci<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=avm-hBvClHjGIrWtDCCRUlBaUFg0AZFv4DZxnIXXlHOUNYc5uSAzbZr-dSt_h76aPaxn43SFfmdC1-HSundwTg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>Absci<\/u><br \/>\n        <\/a> is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X0obpNlaz93NJJ65RM6IC47VmZC86sj7FMWJLpHRASjHApV2X3_QqQOotfnviAnXh5qT4MNXWV3gMm2B5Dt-xCcwaKsZLR2BErcp-oecsbJBbzSghUoMTKO4durdFP1C\" rel=\"nofollow\" target=\"_blank\"><u>Integrated Drug Creation<\/u><\/a>\u2122 platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci\u2019s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XMZxp4tqlMWcOHimWbSxen9-PY3-P4JxPYLOHvgRva5EH98tRwHM5E6Z-oN8uEyu4FYv5l2XfZiFUvhtgsL5WA==\" rel=\"nofollow\" target=\"_blank\"><u>www.absci.com<\/u><\/a> and follow us on LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b4Xb21nP_2CvrHzNP58VHnUCQio_9aGzXuk6Bp6OcX612vmCJAG4wWwrsGejc7DvCSVubrpws1cqYSIkNiFGT0ZPe7E0AQYytlfpwDP5azo=\" rel=\"nofollow\" target=\"_blank\"><u>@absci<\/u><\/a>), X (Twitter) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-fdF7dCcfH2XV-soh-O6a0HzWI_CoTw0ZwChaQqFqmssSrc9UAshd32ugeQ9mEP2OlqGTIWbk_NAHiyOJlLVbw==\" rel=\"nofollow\" target=\"_blank\"><u>@Abscibio<\/u><\/a>), and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UM_cvj_36t-9eb0xL5HuyRUHiucAiprSv5Izrjp87dHybnvR1izE4vtE8cEYt1_7itoeK02-t8ggZTr34fW2iQ==\" rel=\"nofollow\" target=\"_blank\"><u>YouTube<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Alex Khan<br \/>VP, Finance &amp; Investor Relations<br \/>investors@absci.com<\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>press@absci.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTNlNDdiYzMtZTc1NC00YjM2LTk2NzEtYzVlNzE5MTY1YzllLTEyMjE2MzM=\/tiny\/ABSCI-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY. Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company\u2019s investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform unlocks the potential to accelerate time to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-803223","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY. Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company\u2019s investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform unlocks the potential to accelerate time to &hellip; Continue reading &quot;Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-22T13:08:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference\",\"datePublished\":\"2025-01-22T13:08:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/\"},\"wordCount\":245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/\",\"name\":\"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\",\"datePublished\":\"2025-01-22T13:08:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/","og_locale":"en_US","og_type":"article","og_title":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk","og_description":"VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY. Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company\u2019s investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform unlocks the potential to accelerate time to &hellip; Continue reading \"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-22T13:08:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference","datePublished":"2025-01-22T13:08:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/"},"wordCount":245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/","name":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=","datePublished":"2025-01-22T13:08:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNTIzNCM2NzAzNTcyIzIyMTAwODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/803223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=803223"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/803223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=803223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=803223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=803223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}